UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2018 (June 11, 2018)

Kadmon Holdings, Inc. (Exact name of registrant as specified in its charter)

Delaware 001-37841 27-3576929 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.)

450 East 29th Street New York, NY 10016 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code (212) 308-6000

N/A (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

ITEM 7.01 Regulation FD Disclosure

On June 11, 2018, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing the commencement of a public offering of its common stock (the “Public Offering”). A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated in this Item 7.01 by reference.

In addition, on June 11, 2018, the Company released a corporate presentation (the "Corporate Presentation"), a copy of which is attached hereto as Exhibit 99.2 and incorporated in this Item 7.01 by reference.

The information in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended (the “Securities Act”) , or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

This Current Report on Form 8-K, including the exhibits hereto, is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

ITEM 8.01 Other Events

The Company is currently negotiating an amendment to the Credit Agreement (the “2015 Credit Agreement”), dated August 28, 2015, as amended, by and among Kadmon Pharmaceuticals, LLC (a wholly-owned subsidiary of the Company), the guarantors and lenders from time to time party thereto and Perceptive Credit Opportunities Fund, L.P., as collateral representative. The Company expects that the amendment will extend the “Stated Maturity Date” (as defined in the 2015 Credit Agreement) to August 31, 2018 (the “Extension Period”) and provide that amortization payments will not be required as of the effective date of the amendment through the Extension Period. Following the anticipated execution of the amendment, the Company intends to repay approximately $4.7 million on June 18, 2018, representing all amounts due under the 2015 Credit Agreement to GoldenTree Credit Opportunities, LP, GoldenTree Credit Opportunities, Ltd, GoldenTree Insurance Fund Series Interests of the SALI Multi-Series Fund, LP, GT NM, LP, and San Berndino County Employees' Retirement Association. The Company expects that all other material terms of the 2015 Credit Agreement will remain the same during the Extension Period.

In connection with the Public Offering, Slide 12 of the Corporate Presentation is incorporated by reference to this Item 8.01.

The information in this Item 8.01 is being “filed” for purposes of Section 18 of the Exchange Act. The information in this Item 8.01 shall be incorporated by reference into any registration statement of the Company pursuant to the Securities Act.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No. Description

99.1 Press release issued by Kadmon Holdings, Inc., dated June 11, 2018, “Kadmon Announces Proposed Public Offering of Common Stock”.

99.2 Kadmon Holdings, Inc., Corporate Presentation, dated June 11, 2018.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Kadmon Holdings, Inc.

Date: June 11, 2018 /s/ Konstantin Poukalov Konstantin Poukalov Executive Vice President, Chief Financial Officer

Exhibit 99.1

KADMON ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

NEW YORK – June 11, 2018 – Kadmon Holdings, Inc. (NYSE: KDMN)t oday announced its intention to offer and sell shares of its common stock in a public offering pursuant to an existing shelf registration statement. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Jefferies LLC is acting as the sole book-running manager for the offering. H.C. Wainwright & Co., LLC is acting as the lead manager for the offering. Kadmon intends to grant the underwriters a 30-day option to purchase additional shares of its common stock on the same terms and conditions as the shares offered in the public offering.

Kadmon intends to use the net proceeds from the offering for preclinical and clinical development of its lead product candidates, discovery, research and preclinical studies of its other product candidates and for other general corporate purposes.

The securities described above are being offered pursuant to a shelf registration statement on Form S-3 that was declared effective by the Securities and Exchange Commission (the “SEC”) on January 10, 2018. The offering may be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus, when available, may also be obtained by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 821-7388, or by e-mail at [email protected].

This news release is for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale of these securities would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Kadmon Holdings, Inc.

Kadmon Holdings, Inc. is a fully integrated biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the anticipated public offering and the anticipated use of proceeds of the offering. Such statements may be preceded by the words “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We believe that these factors also include, but are not limited to, (i) the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; (ii) our ability to advance product candidates into, and successfully complete, clinical trials; (iii) our reliance on the success of our product candidates; (iv) the timing or likelihood of regulatory filings and approvals; (v) our ability to expand our sales and marketing capabilities; (vi) the commercialization of our product candidates, if approved; (vii) the pricing and reimbursement of our product candidates, if approved; (viii) the implementation of our business model, strategic plans for our business, product candidates and technology; (ix) the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology; (x) our ability to operate our business without infringing the intellectual property rights and proprietary technology of third parties; (xi) costs associated with defending

intellectual property infringement, product liability and other claims; (xii) regulatory developments in the United States, Europe and other jurisdictions; (xiii) estimates of our expenses, future revenues, capital requirements and our needs for additional financing; (xiv) the potential benefits of strategic collaboration agreements and our ability to enter into strategic arrangements; (xv) our ability to maintain and establish collaborations or obtain additional grant funding; (xvi) the rate and degree of market acceptance of our product candidates; (xvii) developments relating to our competitors and our industry, including competing therapies; (xviii) our ability to effectively manage our anticipated growth; (xix) our ability to attract and retain qualified employees and key personnel; (xx) our ability to achieve cost savings and other benefits from our efforts to streamline our operations and to not harm our business with such efforts; (xxi) our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act; (xxii) statements regarding future revenue, hiring plans, expenses, capital expenditures, capital requirements and share performance; (xxiii) litigation, including costs associated with prosecuting or defending pending or threatened claims and any adverse outcomes or settlements, whether or not covered by insurance; (xxiv)the use of proceeds from the anticipated public offering; (xxv) the potential benefits of any of our product candidates being granted orphan drug designation; (xxvi) the future trading price of the shares of our common stock and impact of securities analysts’ reports on these prices; and/or (xxvii) other risks and uncertainties. More detailed information about Kadmon and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the U.S. Securities and Exchange Commission (“SEC”), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed pursuant to Section 13 of the Securities Exchange Act of 1934, as amended, with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Contacts

Ellen Tremaine, Investor Relations (646) 490-2989 [email protected]

Exhibit 99.2

1 Kadmon Holdings, Inc.C orporate PresentationJ une 2018

2 2 DisclaimersT his presentation contains “forward - looking” statements that are based on the beliefs and assumptions and on information currently available to management of Kadmon Holdings, Inc . (the “Company”) . All statements other than statements of historical fact contained in this presentation are forward - looking statements . Forward - looking statements include information concerning the initiation, timing, progress and results of clinical trials of the Company’s product candidates, the timing or likelihood of regulatory filings and approvals for any of its product candidates, and estimates regarding the Company’s expenses, future revenues and future capital requirements . In some cases, you can identify forward - looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology . There are important factors that could cause the Company’s actual results to differ materially from those expressed or implied by the forward - looking statements, including those factors discussed under the caption entitled “Risk Factors” in the Company’s Quarterly Report on Form 10 - Q for the period ended March 31 , 2018 . Forward - looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward - looking statements . Forward - looking statements represent the Company’s beliefs and assumptions only as of the date of this presentation . Although the Company believes that the expectations reflected in the forward - looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or achievements . Except as required by law, the Company assumes no obligation to publicly update any forward - looking statements for any reason after the date of this presentation to conform any of the forward - looking statements to actual results or to changes in its expectations . We have filed a registration statement (File No. 333 - 222364), including a prospectus, with the SEC for the offering to which thi s communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has fil ed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on t heS EC websitea t www.sec.gov . Alternatively, the issuer, any underwriter, or any dealer participating in the offering will arrange to send you the prospect us, ifa nd when available, if you request it by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Mad iso n Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821 - 7388, e - mail: [email protected] .

3 3 Innovative Pipeline for Significant Unmet Medical Needs Clinical - Stage Compounds Indication Preclin. Phase 1 Phase 2 Status Inflammatory and Fibrotic Diseases KD025 (ROCK2 inhibitor) Chronic Graft - Versus - Host Disease (cGVHD) Phase 2 ongoing; Pivotal trial planned Q3 2018 Scleroderma (Systemic Sclerosis) Phase 2 planned Q4 2018 Idiopathic Pulmonary Fibrosis (IPF)P hase 2 ongoing Moderate to Severe Psoriasis Phase 2 ongoingG eneticD iseases Tesevatinib Autosomal Dominant Polycystic Kidney Disease (ADPKD) Phase 2 ongoing Autosomal Recessive Polycystic Kidney Disease (ARPKD) Phase 1 ongoing KD034 Wilson’s Disease Two ANDAs submitted

4 ROCK Inhibitor Platform Inflammatory and Fibrotic Diseases

5 5 The Role of the ROCK Signaling Pathway ROCK Signaling Pathway Plays a Key Role in Multiple Tissue Types  Rho - associated coiled - coil kinase (ROCK) is a serine/threonine kinase that mediates a wide range of functions, including cell movement, shape, differentiation and function 1  Two isoforms exist: ROCK1 and ROCK2, with both overlapping and non - redundant functions 1  ROCK is ubiquitously expressed, with high levels in smooth muscle tissues, brain and heart 2  ROCK inhibition has therapeutic potential in a wide range of diseases 1 Small GTPases . 2014; 5: e29846. 2 Post - Genomic Cardiology (Second Edition). 2014, Pages 183 – 215

6 6 ROCK2 Rebalances Immune Response to Treat Immune Dysfunction ROCK2 Inhibition Downregulates STAT3 and Upregulates STAT5 Pathways STAT3 (Th17) STAT5 (Treg) Inflammation Resolution Inflammation Resolution STAT3 (Th17) STAT5 (Treg) ROCK2 Activation ROCK2 Inhibition ROR g t IRF4  ROCK2 inhibition down - regulates pro - inflammatory Th17 responses and increases Treg function, helping to resolve immune dysregulation– Reduces STAT3 phosphorylation and increases STAT5 phosphorylation  ROCK2 inhibition rebalances immune response instead of suppressing entire immune system

7 7 ROCK is the Common Pathway of Initiating Factors in Fibrosis ROCK Regulates Multiple Pro - Fibrotic Processes, Including Myofibroblast Activation  ROCK is downstream of major pro - fibrotic mediators, including: – Transforming growth factor beta (TGF - β ) – Connective tissue growth factor (CTGF)– Lysophosphatidic acid (LPA)  ROCK regulates fibroblast differentiation to myofibroblasts, a defining feature of pathologic fibrosis  ROCK mediates stress fiber formation  ROCK regulates transcription of pro - fibrotic genes, including CTGF and alpha - smoothm uscle actin ( α - SMA) ROCK ROCK CTGF Stress fiberf ormation MKL1 MKL1 MKL1 Pro - fibroticg enes CTGF Myofibroblast Cell Am J Pathol. 2015 Apr;185(4):909 - 12.

8 8 KD025: A ROCK2 - Selective Inhibitor KD025 is Kadmon’s Lead ROCK2 Inhibitor In Phase 2 Development  KD025 is a selective oral ROCK2 inhibitor in Phase 2 clinical development for inflammatory and fibrotic diseases – Demonstrated a favorable tolerability profile and clinical activity in 8 completed clinical trials – To date, more than 350 subjects have been dosed with KD025 for inflammatory or fibrotic diseases ora s healthy volunteers  KD025 half - life: 6 - 8 hours  Linear PK within therapeutic exposure range  Demonstrated clinical activity as low as 200 mg QD – Achieving median C max ~2,100 ng/mL (~5 m M) and AUC 0 - 24 ~10,000 h.ng/mL – Little to no accumulation — steady - state levels comparable to single dose levels in QD regimen  Exposure is comparable in healthy volunteers and in inflammatory andf ibrotic disease patients

9 9 KD025: Chronic Graft - Versus - Host - Disease (cGVHD) cGVHD: Complication Following HSCT  Life - threatening condition following stem cell transplant from blood or bone marrow( hematopoietic stem cell transplantation (HSCT))  Transplanted immune cells (graft) attackh ealthy cells (host), leading to inflammation and fibrosis in multiple organs cGVHD demonstrates common features of bothi nflammatory andf ibrotic diseases: – Immune system over - activation – Fibrotic response  Leading cause of post - transplant morbidity and mortality KD025 – c GVHD Summary  In preclinical models, KD025 reversed manifestations of cGVHD: – Targeted immunologic and fibrotic components of cGVHD – Did not inhibit the immune system’s ability to fight infections in mice challenged with murine CMV  Positive results from ongoing Phase 2 clinical trial in adults with steroid - dependento r steroid refractory cGVHD  Received Orphan Drug Designation in October 2017

10 10 cGVHD Treatment Landscape Currently Available cGVHD Therapies  Steroids are first - line treatment for cGVHD  Ibrutinib received FDA approval in August 2017 fora dults with cGVHD after failure of one or more lines ofs ystemic therapy 1  Enrollment criteria required 25% body surface areae rythematous rash or >4 total mouth score  Approval was based on an open - label, single - arm, Phase 1b/2 study in 42 patients Ibrutinib efficacy 1,2 :– Overall response rate (ORR) was 67% (28/42 patients) – 48% (20/42) of patientss ustained response for ≥20 weeks  Ibrutinib safety: – 24% of patients discontinued duet o adverse reactions – Fatigue and pneumonia were the most common adverse reactions leading to discontinuation Ruxolitinib in Development for GVHD  Two ongoing Phase 2 trialsi n steroid - refractory acute GVHD (aGVHD ): – REACH1: Single - arm study; results expected Q2 2018– REACH2: Randomized vs. BAT 3  Ongoing Phase 3 trial in steroid - refractory cGVHD (REACH3): – Excludes patients who have received 2 or more systemic treatments forc GVHD in addition to corticosteroids ± CNI 4 and any systemic treatment – Randomized vs. BAT; optional crossover to ruxolitinib after Cycle 61 Co - developed by Janssen and AbbVie; brand name Imbruvica ® 2 Imbruvica label3 Best Available Therapy 4 Calcineurin inhibitor

11 11 Ongoing Ph2 Trial of KD025 in cGVHD: Design and Key Endpoints Cohort 1: 200mg QD (n=16) Cohort 2: 200mg BID (n=16) Cohort 3: 400mg QD (n= 16 ) Enrollment per trial design; actual enrollment: Cohort 1 (n=17); Cohort 2 (n=16); Cohort 3 ( ongoing ) 1 2014 National Institutes of Health (NIH) Consensus Conference overall response criteria KD025 - 208 Key Eligibility Criteria: • Adults with steroid - dependent or steroid - refractory cGVHD • Have persistent active cGVHD after at least 2m onths of steroid therapy • Receiving glucocorticoid therapy +/ - calcineurin inhibitor therapy forc GVHD • No more than 3 prior lines of treatment forc GVHD Key Endpoints: • Overall Response Rate( ORR), per 2014 NIH criteria 1 • Safety and tolerability ofK D025 in patients with cGVHD • Duration of response andr esponse by organs ystem • Changes in corticosteroid and calcineurin inhibitor dose

12 12 KD025 Associated With Robust Overall Responses Approximately Two - Thirds of Patients Achieved a Clinical Response with KD025  KD025 was well tolerated: – No treatment - related SAEs – No apparent increased risk of infection ORRs of 65% and 69% in Cohorts 1 and 2, respectively – Observed CRs in multiple organs, including in organs withf ibrotic disease  Durable responses: 8/17 (47%) patients in Cohort 1 and6 /16 (38%) patients in Cohort 2 have sustained response for ≥ 20 weeks – Durability data continue to mature across both cohorts  Patients were able to reduce doses of corticosteroids and other immunosuppressants– 37% and 26% reductions in median corticosteroid dose in Cohorts 1 and 2, respectively – 5/33 patients (15%) have completely discontinued steroids  Lee Symptom Scale Score improvements (≥7 point reduction) in 55% of patients in Cohort 1 and 2 Data as of 5/2/2018

13 13 KD025 in cGVHD: Regulatory Pathway Planned Regulatory Pathway for KD025 in cGVHD  FDA Type C meeting with Kadmon on March 22, 2018 to receive guidance on development pathway  Based on FDA guidance, Kadmon plans to initiatea n open - label pivotal Phase 2 trial in cGVHD – Two dose levels: KD025 200 mg QD and KD025 200 mg BID  Either dose may be considered by the FDA as the registrational dose– Primary endpoint: ORR, defined as percentage of patients who meet 2014 NIH criteria,s upported by a key secondary endpoint of duration of response (DOR)  We believe an ORR of at least 30% would be considered clinically meaningful in this population  Trial initiation anticipated Q3 2018

14 14 KD025 - 213: Planned Pivotal Trial of KD025 in cGVHD KD025 200 mg BID (n=63) KD025 200 mg QD (n=63) Treat to progression Primary Endpoint: • ORR, per 2014 NIH criteria Key SecondaryE ndpoints: • Durability of response • Response by organs ystem • Lee Symptom Score • Changes in corticosteroid and calcineurin inhibitor dose • Failure - free survival • PharmacokineticsR KD025 - 213 Key Eligibility Criteria: • Adults who have had HSCT• Have active cGVHD • Received at least two prior lines of systemic therapy forc GVHD

15 15 KD025 - 209: Planned Phase 2 Clinical Trial in Scleroderma Scleroderma (Systemic Sclerosis) Background  Scleroderma (also known as systemic sclerosis) is a chronic multi - system disease characterized by skin thickening and internal organ fibrosis – Approximately 75,000 to 100,000 people in the U.S. are living with scleroderma  There are no FDA - approved therapies currently available for scleroderma KD025– Scleroderma Summary  ROCK inhibition has demonstrated potential in preclinical models for scleroderma  Currently designing a Phase 2, placebo - controlled study of KD025 for scleroderma (KD025 - 209) – Study protocol under development  Initiation of Phase 2 clinical study planned Q4 2018

16 16 KD025: Idiopathic Pulmonary Fibrosis (IPF) IPF: Major Unmet Medical Need IPF is a progressive fibrotic disease of the lungs– Believed to be caused by repetitive environmental injury to lining of the lungs and resulting abnormal wound - healing responses– Prolonged activation of wound - healing responses can result in permanent scarring, organ malfunction and death  Two approved therapies, Esbriet ® (pirfenidone) and Ofev ® (nintedanib)  Need for additional effective IPF therapies KD025 – IPF Summary  KD025 reduced fibrosis in multiple preclinical models: – Reduced lung fibrosis in bleomycin mouse model – Reduced fibrosis in cGVHD mouse model  Demonstrated clinical activity in ongoing Phase 2 clinical trial in adults with IPF whop reviously received pirfenidone and/or nintedanib or been offered both

17 17 KD025 in IPF: Demonstrated Clinical Activity 1  KD025 - 207: Open - label, 24 - week trial of3 9 patients randomized 2:1 to receive KD025 400 mg QD or Best Supportive Care (BSC) KD025 slowed the decline in lung function in IPF patients at 24 weeks 2 : – Absolute change in FVC of - 50 mL in KD025 patients (n=24), compared to- 175 mL with BSC (n=11) – KD025 patients demonstrated 1.0% FVC decline, compared to 5.0% with BSC– 29% of KD025 patients experienced an FVC % predicted decline ≥ 5%, compared to 55% with BSC  KD025 was well tolerated, with no drug - related SAEs – 90% of patients on KD025 elected to continue on treatment beyond 24 weeks  Trial expanded toi nclude an additional 40 patients, increasing total enrollment to ~81 patients 1 Conclusions based on Modified ITT (mITT) population:R andomized patients who received at least 1 KD025 dose or completed Visit 1 on BSC, and who had evaluable baseline and at least one evaluable post - baseline FVC measure( linear extrapolation) 2 Data cutoff date: March 13, 2018; presented at ATS 2018

18 18 KD025 Clinical Activity Maintained Through Week4 8 1  Range of Δ FVC in treatment arms of Phase 3 studies of approved IPF therapiesn intedanib and pirfenidone 2,3 Range of Δ FVC in placeboa rms of Phase 3 studies of approved IPF therapies 2,3 1 Not a head - to - head comparison 2 Supplement to: N Engl J Med 2014;370:2071 - 82. Page 18, Table S5: Secondary lung function endpoints in INPULSIS™ - 1 and INPULSIS™ - 2 at week 52 (pooled data).0 BSC - 175 mL (n=9)K D025 - 50 mL (n=20) KD025 - 120 mL ( n=12) 4 -400 -350 -300 -250 -200 -150 -100 -50 0 0 12 24 36 48 Change in FVC (mL)T ime (Weeks) 0 3 NE ngl J Med 2014;370:2083 - 92. DOI: 10.1056/NEJMoa1402582.Page 2088, Fig 2B (ASCEND). 4 N=12r eflects patients with week 48 FVC, with no imputation Patients who Continue on KD025 to Week 48 Maintain Slowed Rate of FVC Decline (mITT Population)

19 19 Wilson’s Disease Background  Wilson’s Disease is a genetic disorder characterized by an inability to excrete copper – Leads to severe hepatic, neurologic, psychiatric and/or ophthalmic abnormalities – 10,000 living with Wilson’s Disease in the United States – Currently available treatments require colds torage and have inconvenient dosing schedules KD034: Enhanced Formulations of Trientine for Wilson’s Disease KD034 – Wilson’s Disease Summary  Kadmon’s KD034 portfolio contains a trientine hydrochloride formulation packaged to optimize Wilson’s Disease management for patients who are intolerant of penicillamine – Includes a bottled generic 250 mgc apsule formulation and a generic 250 mgc apsule formation in blister packagingt hat offers room temperature stability – Stability and bioequivalence studies completed  Kadmon has submitted two ANDAs for KD034 to the FDA – Bottled generic: ANDA submitted December 5, 2016 – Blister pack: ANDA submitted March 31, 2017  Kadmon is in dialogue with the FDA to work towards regulatory approval

20 Preclinical Research

21 21 Kadmon Drug Discovery Platform Robust Drug Discovery Platform  24 - person team developing small molecules and biologics  Lead program: Third - generation ROCK inhibitors optimized for clinical development Platform Target Potential Indication(s) Small Molecules Rho associated coiled - coil containingp rotein kinase (ROCK) inhibitorsL ead candidate: KD045 Fibrotic and inflammatory diseases( KD045 IND anticipated 2H 2019) Glucose transport (GLUT) inhibitors Autoimmune diseases Biologics IL - 15 - containing fusion proteins Lead candidate: KD033 (anti - PD - L1/IL - 15) Immuno - oncology (KD033 IND anticipated 2H 2019)

22 22 KD045, Lead ROCK Inhibitor Candidate Kadmon ROCK Inhibitor Program Overviewh inge Activation loop G - loop KD045  Discovery goal: Identify and develop proprietary third - generation ROCK inhibitors optimized for clinical development – Develop candidates with improved potency, specificity, “drug - like” properties and safety  Development goal: Validate the role of ROCK signaling in fibrotic and inflammatory disease  Lead preclinical candidate selected (KD045) – Demonstrated activity in multiple in vivo pharmacology models, including inm odels of bleomycin - induced lung fibrosis and renal fibrosis – IND anticipated 2H 2019

23 23 KD033: Lead IL - 15 Fusion Platform Candidate KD033 (anti - PD - L1/IL - 15 Fusion Protein ): IND Anticipated 2H 2019 Anti - PD - L1 alone, 10 mg/kg Anti - PD - L1/IL - 15 (KD033 surrogate ), 3.3 mg/kg Vehiclen =12D osing, once a week Day 54 Day 77 Day 124 % Survival Days after tumor inoculation 1 st Rechallenge 2 nd Rechallenge 3 rd Rechallenge 1 MC38 colon adenocarcinoma model  KD033 combines a master regulator (PD - L1) and a stimulator (IL - 15) of immune response, targeted to the tumor site  In vitro , KD033 has shown to block PD - 1/PD - L1 signaling and to activate IL - 15R in cell - based assays  KD033 - treated mice survived tumor rechallenge, suggesting that KD033 induces immune system memory 1

24 24 Company Summary Leader in R&D ofR OCK Inhibitors  KD025: SelectiveR OCK2 inhibitor in Phase 2 clinical development: – Open - label, dose - finding trial in cGVHD– Randomized, open - label trial in IPF  Generateda portfolio of preclinical ROCK inhibitors for inflammatory and fibrotic diseases– Lead candidate identified (KD045); IND anticipated 2H 2019B iologics Platform  Developing unique oncology product candidates, including KD033, an anti - PD - L1/IL - 15 fusion protein Commercial Platform  Supports development and future commercialization of clinical - stage product candidates  KD034: Generic trientine hydrochloride formulation in development for Wilson’s disease Clinical Program in Polycystic Kidney Disease Tesevatinib: Potent EGFR inhibitor in ongoing clinical trials for polycystic kidney disease: – Phase 2 randomized, double - blind, placebo - controlled trial in autosomal dominant polycystic kidney disease – Phase 1 trial in autosomal recessive polycystic kidney diseaseS ignificant MeiraGTx Ownership  Kadmon transferred its gene therapy platform to MeiraGTx Limited and retains a 17.7% ownership( MeiraGTx Form S - 1 filed May 14, 2018)

25 25 Financial Profile KDMN Financial Summary  Cash and cash equivalents of $49.2 million as of March 31, 2018  78,794,746 common shares outstanding as of May 4, 2018  Trades on the NYSE under the ticker symbol “KDMN”